PCM
EBS icon

Palisade Capital Management’s Emergent Biosolutions EBS Stock Holding History

Palisade Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
515,059
-686,264
-57% -$5.74M 0.19% 161
2026
Q1 		$9.97M Sell
1,201,323
-64,443
-5% -$667K 0.33% 96
2025
Q4 		$15.6M Sell
1,265,766
-160,253
-11% -$1.72M 0.46% 80
2025
Q3 		$12.6M Buy
1,426,019
+326,260
+30% +$2.54M 0.34% 97
2025
Q2 		$7.02M Sell
1,099,759
-41,830
-4% -$239K 0.2% 134
2025
Q1 		$5.55M Buy
1,141,589
+202,857
+22% +$1.68M 0.16% 155
2024
Q4 		$8.97M Buy
938,732
+188,802
+25% +$1.73M 0.24% 116
2024
Q3 		$6.26M Buy
749,930
+296,101
+65% +$2.69M 0.17% 145
2024
Q2 		$3.1M Sell
453,829
-7,819
-2% -$33.6K 0.08% 205
2024
Q1 		$1.17M Buy
461,648
+11,236
+2% +$25.3K 0.03% 279
2023
Q4 		$1.08M Sell
450,412
-58,913
-12% -$138K 0.03% 298
2023
Q3 		$1.73M Sell
509,325
-29,093
-5% -$161K 0.05% 245
2023
Q2 		$3.96M Buy
538,418
+24,547
+5% +$228K 0.11% 185
2023
Q1 		$5.32M Buy
513,871
+12,199
+2% +$147K 0.14% 166
2022
Q4 		$5.92M Sell
501,672
-25,317
-5% -$392K 0.16% 166
2022
Q3 		$11.1M Sell
526,989
-39,091
-7% -$1.09M 0.31% 105
2022
Q2 		$17.6M Buy
566,080
+5,671
+1% +$194K 0.48% 71
2022
Q1 		$23M Sell
560,409
-24,548
-4% -$1.08M 0.53% 66
2021
Q4 		$25.4M Sell
584,957
-58,507
-9% -$2.65M 0.51% 69
2021
Q3 		$32.2M Buy
643,464
+40,984
+7% +$2.48M 0.7% 42
2021
Q2 		$38M Sell
602,480
-23,489
-4% -$1.51M 0.86% 25
2021
Q1 		$58.2M Buy
625,969
+46,960
+8% +$4.81M 1.37% 5
2020
Q4 		$51.9M Buy
579,009
+150,134
+35% +$13.8M 1.33% 5
2020
Q3 		$44.3M Buy
428,875
+58,825
+16% +$6.34M 1.31% 6
2020
Q2 		$29.3M Buy
370,050
+169,448
+84% +$12.6M 0.93% 14
2020
Q1 		$11.6M Buy
200,602
+75,686
+61% +$4.36M 0.41% 80
2019
Q4 		$6.74M Buy
+124,916
New +$6.78M 0.19% 152
2016
Q3 		– Sell
-7,155
Closed -$201K – 568
2016
Q2 		$201K Buy
+7,155
New +$281K 0.01% 518

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Palisade Capital Management's EBS Position: Q2 2026 in Review

Palisade Capital Management reduced its Emergent Biosolutions (EBS) stake by 57% in Q2 2026, selling an estimated $5.74M and leaving 515,059 shares worth $4.32M. The position accounts for 0.19% of the portfolio, ranked #161.

Palisade Capital Management first reported a position in EBS in Q2 2016 and has held it in 28 quarters since. The position peaked at $58.2M in Q1 2021. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Palisade Capital Management held 515,059 shares of Emergent Biosolutions worth $4.32M as of Q2 2026.
  • Palisade Capital Management sold 686,264 Emergent Biosolutions shares in Q2 2026, an estimated $5.74M.
  • Emergent Biosolutions made up 0.19% of Palisade Capital Management's portfolio in Q2 2026, its #161 holding.
  • Palisade Capital Management first reported a position in Emergent Biosolutions in Q2 2016 and has held it in 28 quarters since.
  • Palisade Capital Management's Emergent Biosolutions position peaked at $58.2M in Q1 2021.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Palisade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.